Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05459051
Other study ID # P91528
Secondary ID 22HH7546
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date April 8, 2025

Study information

Verified date March 2024
Source Imperial College London
Contact Fiyyaz Ahmed-Jushuf, MBBS MRCP
Phone 020 7594 5735
Email fiyyaz.ahmed-jushuf09@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

ORBITA-FIRE is a randomised, double-blinded, placebo controlled experimental study that will identify the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) thresholds that correlate with symptoms of angina for 58 patients measured invasively under experimental conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date April 8, 2025
Est. primary completion date April 8, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eligibility for percutaneous coronary intervention (PCI) due to angina or angina-equivalent symptoms on exertion - Anatomical evidence of significant single-vessel coronary stenosis defined by either: - =70% stenosis on invasive coronary angiography (ICA) - Severe stenosis on CT coronary angiography (CTCA) - Physiological evidence of ischaemia with a positive test on at least one of the following: - Stress echocardiography - Cardiac magnetic resonance perfusion - Myocardial perfusion scintigraphy - Invasive metrics of coronary physiology Exclusion Criteria: - Age <18 years - Recent acute coronary syndrome - Previous coronary artery by-pass graft - Significant left main stem disease - Multivessel disease (defined as >50% angiographic stenosis in other vessels) - Chronic total occlusion in the target artery - Moderate to severe valvular disease - Moderate to severe left ventricular impairment - Chronotropic incompetence with a pacemaker - Contraindication to PCI or a drug-eluting stents - Contraindication to antiplatelet therapy - Contraindication to adenosine - Moderate to severe respiratory disease - Physical inability to exercise - Pregnant - Inability to consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Rest-angina physiological assessment
The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
Exercise-angina physiological assessment
The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.

Locations

Country Name City State
United Kingdom Mid and South Essex NHS Foundation Trust Basildon
United Kingdom Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust Bournemouth
United Kingdom Imperial College NHS Trust London
United Kingdom Royal Free Hospital NHS Foundation Trust London
United Kingdom St George's University Hospitals NHS Foundation Trust London
United Kingdom Portsmouth Hospitals NHS Trust Portsmouth

Sponsors (6)

Lead Sponsor Collaborator
Imperial College London Mid and South Essex NHS Foundation Trust, Portsmouth Hospitals NHS Trust, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The FFR and NHPR value at which the patient experiences angina in a rest state Values 0.00-1.00 (Lower = More significant disease) Intra-procedural
Primary The FFR and NHPR value at which the patient experiences angina in an exercise state Values 0.00-1.00 (Lower = More significant disease) Intra-procedural
Secondary The FFR difference between the rest and exercise states Values 0.00-1.00 (Lower = More significant disease) Intra-procedural
Secondary The NHPR difference between the rest and exercise states Values 0.00-1.00 (Lower = More significant disease) Intra-procedural
Secondary Angina severity score at the angina threshold The patient scores the severity of the angina experienced during the procedure between 0-10 (Higher = More severe) Intra-procedural
Secondary Angina similarity score at the angina threshold The patient scores the similarity of the angina experienced during the procedure against the angina experienced before the procedure between 0-10 (Higher = Most similar) Intra-procedural
Secondary Angina symptom type at the angina threshold The patient will list all symptoms experienced at the angina threshold Intra-procedural
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Not yet recruiting NCT02550301 - Does Mean Platelet Volume Change With Clopidogrel N/A
Completed NCT02252406 - Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Phase 4
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Not yet recruiting NCT01162902 - Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Phase 4
Completed NCT02126150 - United Coronary Biobanks N/A
Completed NCT01328470 - Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease Phase 4
Completed NCT01769079 - Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina Phase 4
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00263263 - RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. Phase 2
Active, not recruiting NCT04929496 - Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Completed NCT06464276 - Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Completed NCT01974492 - Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting N/A
Completed NCT01990924 - Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4
Terminated NCT01394848 - Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy Phase 4